CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Single Arm Study Assessing Efficacy & Safety of Nivolumab Plus Ipilimumab in Nonresectable/Metastatic Sarcoma and Endometrial Carcinoma Patients With Somatic Deficient MMR as a Selection Tool

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02982486
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:45.944033+00:00
Published At: 2017-11-01T00:00:00+00:00
Record Updated At: 2017-11-01
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Soft Tissue Sarcoma", "Bone Sarcoma", "Chondrosarcoma", "Gastrointestinal Stromal Sarcoma", "Ewing\u0027s Tumor Metastatic", "Ewing\u0027s Tumor Recurrent", "Osteosarcoma", "Desmoplastic Small Round Cell Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2017-11-01"
protocolSection.identificationModule.nctId: "NCT02982486"
protocolSection.identificationModule.officialTitle: "A Phase II Single Arm Study Assessing Efficacy \u0026 Safety of Nivolumab Plus Ipilimumab in Nonresectable/Metastatic Sarcoma and Endometrial Carcinoma Patients With Somatic Deficient MMR as a Selection Tool"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.